Rising research and development (R&D) expenditures by pharmaceutical companies are, in part, a consequence of changing industry structure, particularly the rise of the biotechnology sector. The creation of a market for biomedical science and increased vertical competition within the industry are likely to spur innovation and raise productivity, but they also could induce socially wasteful spend...

To control expenditures and use medications appropriately, the Medicare drug coverage program has established pharmacy utilization management (PUM) measures. This article assesses the effects of these strategies on the care of seniors. The literature suggests that although caps on drug benefits lower pharmaceutical costs, they may also increase the use of other health care services and hurt hea...

Health policy-makers worldwide have adopted different Reference Pricing (RP) systems for pharmaceuticals. Systems may differ concerning their effects on pharmaceutical prices, firms’ strategies, market structure, public and private expenditure, health outcomes and Research and Development (R&D) investments. We present evidence from a recent systematic review of the effects of RP across differen...

In three field studies, we explore the impact of providing employees and teammates with prosocial bonuses, a novel type of bonus spent on others rather than on oneself. In Experiment 1, we show that prosocial bonuses in the form of donations to charity lead to happier and more satisfied employees at an Australian bank. In Experiments 2a and 2b, we show that prosocial bonuses in the form of expe...

The pharmaceutical industry spends roughly 15 billion dollars annually on detailing – providing gifts, samples, free pens, trips, honoraria and other inducements – to physicians in order to encourage them to prescribe their drugs. In response, a movement to regulate pharmaceutical marketing emerged. In this article, we use a dataset that captures 189 million psychotropic prescriptions written i...

A vast majority of the EU countries are witnessing a rise in the share of public pharmaceutical spending in the total drugs expenditure. This urges governments to adopt cost containment measures through more stringent norms in their pharmaceutical policies. The aim of this paper is to review the existing pharmaceuticals cost-containment policies in the EU in order to illustrate the complexity o...

background health expenditures are divided in two parts of public and private health expenditures. public health expenditures contain social security spending, taxing to private and public sectors, and foreign resources like loans and subventions. on the other hand, private health expenditures contain out of pocket expenditures and private insurances. each of these has different effects on the ...

background one of the main objectives of health systems is the financial protection against out-of-pocket (oop) health expenditures. oop health expenditures can lead to catastrophic payments, impoverishment or poverty among households. in iran, health sector evolution plan (hsep) has been implemented since 2014 in order to achieve universal health coverage and reduce the oop health expenditures...